RenovoRx Announces Publication of Positive Early-Stage Clinical Data in International Peer-Reviewed Journal, The Oncologist®
July 31, 2024 08:30 ET
|
RenovoRx, Inc.
Published data shows that chemotherapy delivered via TAMP™ with prior chemoradiation in Locally Advanced Pancreatic Cancer (LAPC) observed an Overall Survival (OS) of 27-months Targeted chemotherapy...
RenovoRx Announces Acceptance for Publication in the International Peer-Reviewed Journal, The Oncologist®
July 08, 2024 08:30 ET
|
RenovoRx, Inc.
LOS ALTOS, Calif., July 08, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology...
University of Nebraska Medical Center Launches Patient Enrollment for RenovoRx’s Pivotal Phase III TIGeR-PaC Clinical Trial
June 26, 2024 08:30 ET
|
RenovoRx, Inc.
LOS ALTOS, Calif., June 26, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology...
RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships
June 10, 2024 08:30 ET
|
RenovoRx, Inc.
LOS ALTOS, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology...